AUTL 241220 2.50P (AUTL241220P2500) Stock Options, News & Quotes

US OptionsDetailed Quotes

AUTL241220P2500

Watchlist

0.05
0.000.00%

15min DelayClose Nov 21 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Goldman Sachs Upgrades Autolus Therapeutics(AUTL.US) to Buy Rating, Raises Target Price to $7.6
Moomoo NewsNov 19 03:36 ET · Ratings
Autolus Therapeutics Analyst Ratings
BenzingaNov 18 08:03 ET · Ratings
Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7
MT NewswiresNov 18 07:51 ET · Ratings
Autolus Therapeutics: FDA Approval of Aucatzyl De-Risks Platform, Significant Upside Anticipated
TipRanksNov 18 06:16 ET
This InterContinental Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
BenzingaNov 15 08:12 ET
Redburn Atlantic Initiates Autolus Therapeutics(AUTL.US) With Buy Rating, Announces Target Price $13
Moomoo NewsNov 15 05:34 ET · Ratings

Comments

stderr

Nov 12 12:21

$Autolus Therapeutics (AUTL.US)$ Nothing happened?

Momomimk

Nov 11 03:23

$Autolus Therapeutics (AUTL.US)$

Share Your Profit/Loss

Jaguar8

Nov 8 16:37

FDA approval. On my Monday, watchlist too

$Autolus Therapeutics (AUTL.US)$

This_Guy

Nov 8 16:31

$Autolus Therapeutics (AUTL.US)$
ya I'm getting in here

Jaguar8

Nov 8 15:41

NEWS

$Autolus Therapeutics (AUTL.US)$
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
• AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy)
• Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL
• Conference call to be held on November 11 at 08:30 am EST/13:3...